Your browser doesn't support javascript.
loading
Importance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination.
Sanders, Andrew J; Owen, Sioned; Morgan, Liam D; Ruge, Fiona; Collins, Ross J; Ye, Lin; Mason, Malcolm D; Jiang, Wen G.
Afiliación
  • Sanders AJ; Cardiff China Medical Research Collaborative (CCMRC), Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
  • Owen S; Cardiff China Medical Research Collaborative (CCMRC), Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
  • Morgan LD; Alfred Russel Wallace Building, Upper Glyntaff, University of South Wales, Pontypridd, UK.
  • Ruge F; Cardiff China Medical Research Collaborative (CCMRC), Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
  • Collins RJ; Cardiff China Medical Research Collaborative (CCMRC), Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
  • Ye L; Cardiff China Medical Research Collaborative (CCMRC), Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
  • Mason MD; Cardiff China Medical Research Collaborative (CCMRC), Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
  • Jiang WG; Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
Oncotarget ; 10(59): 6362-6377, 2019 Oct 29.
Article en En | MEDLINE | ID: mdl-31695844
Activated Leukocyte Cell Adhesion Molecule (ALCAM) has been linked to the progression of numerous human cancers, where it appears to play a complex role. The current study aims to further assess the importance of ALCAM in prostate cancer and the prognostic potential of serum ALCAM as a biomarker for prostate cancer progression. Here we demonstrate enhanced levels of tissue ALCAM are associated with metastasis. Additionally, elevated serum ALCAM is indicative of progression and poorer patient outlook, and demonstrates comparable prognostic ability to PSA in terms of metastasis and prostate cancer survival. ALCAM suppression enhanced proliferation and invasiveness in PC-3 cells and motility/migration in PC-3 and LNCaP cells. ALCAM suppressed PC-3 cells were generally less responsive to HGF and displayed reduced MET transcript expression. Furthermore a recombinant human ALCAM-Fc chimera was able to inhibit LNCaP cell attachment to HECV and hFOB1.19 cells. Taken together, ALCAM appears to be a promising biomarker for prostate cancer progression, with enhanced serum expression associated with poorer prognosis. Suppression of ALCAM appears to impact cell function and cellular responsiveness to certain micro environmental factors.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncotarget Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncotarget Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos